UroToday - A Phase II Randomized, Placebo-Controlled Clinical Trial of Purified Isoflavones in Modulating Steroid Hormones in Men Diagnosed With Localized Prostate Cancer - Abstract

[Guest guest]

http://www.urotoday.com/browse_categories/prostate_cancer/a_phase_ii_randomized_placebocontrolled_clinical_trial_of_purified_isoflavones_in_modulating_steroid_hormones_in_men_diagnosed_with_localized_prostate_cancer__abstract.html

To read

the original article go to medical library or PubMed to purchase article.

Friday, 28 December 2007

Department

of Interdisciplinary Oncology, H. Lee Moffitt Cancer Center & Research

Institute, Tampa, FL

Our

purpose was to evaluate the safety and effectiveness of purified isoflavones in

producing an increase in plasma isoflavones and a corresponding change in serum

sex hormone binding globulin (SHBG) and steroid hormone levels in men diagnosed

with early stage prostate cancer. In this Phase II randomized, double-blinded, placebo-controlled

trial, 53 prostate cancer patients with a Gleason score of 6 or below were

supplemented with 80 mg purified isoflavones or placebo for 12 weeks. Changes

in plasma isoflavones, serum steroid hormones, and safety markers were analyzed

from baseline to 12 wk. A total of 50 subjects completed the study. Although

significant increases in plasma isoflavones (P < 0.001) was observed with no

clinical toxicity, the corresponding modulation of serum SHBG, total estradiol,

and testosterone in the isoflavone-treated group compared to men receiving

placebo was nonsignificant. Increasing plasma isoflavones failed to produce a

corresponding modulation of serum steroid hormone levels in men with localized

prostate cancer. The study establishes the need to explore other potential

mechanisms by which prolonged and consistent purified isoflavone consumption

may modulate prostate cancer risk.

Written

by

Kumar NB, Krischer JP, K, Riccardi D, Besterman-Dahan K, Salup R, Kang L,

Xu P, Pow-Sang J.

Reference

Nutr

Cancer. 2007;59(2):163-8

PubMed

Abstract

PMID:18001210